Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA 19454.
Published March 3, 2021 · Recall initiated: February 10, 2021
Summary
FDA records drug Class II recall D-0271-2021, published March 3, 2021 and initiated February 10, 2021. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 50 vials; Lot: Lot # 31326582B, exp. date 02/2022; Lot # 31326964B, exp. date 04/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Teva Pharmaceuticals USA
- Distributor
- Product was distributed nationwide in the USA and Puerto Rico.
- Lot
- Lot # 31326582B, exp. date 02/2022; Lot # 31326964B, exp. date 04/2022
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAMimvey (estradiol and norethindrone acetate tablets USP), 1 mg/0.5 mg, packaged in cartons of 28 Tablets, RxFebruary 9, 2022
- FDADoxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets 10 mg/10 mg, 100-count bottle, RxFebruary 9, 2022
- FDAMimvey (estradiol and norethindrone acetate tablets USP) 1 mg/0.5 mg, packaged in cartons of 28 Tablets, RxFebruary 9, 2022
- FDATretinoin Capsules, 10 mg, 100 count bottle, Rx Only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454,February 9, 2022
- FDAIrinotecan Hydrochloride Injection, USP, 40 mg/2 mL (20 mg/mL), 2 mL Single-Dose Vial, Rx Only, DistributedMarch 3, 2021
- FDADesmopressin Acetate Injection USP, 4 mcg/mL, 1 mL Preserved Vial (NDC 0703-5051-01), packaged in 10X1 mLMarch 3, 2021
Questions about this recall
Was Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA 19454. recalled?
Yes. FDA published recall D-0271-2021 on March 3, 2021. Reported hazard: Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.
What should I do if I have this product?
Voluntary: Firm initiated · Letter